Search results for " Combination"

showing 10 items of 923 documents

Synergy of spatial frequency and orientation bandwidth in texture segregation

2021

Defining target textures by increased bandwidths in spatial frequency and orientation, we observed strong cue combination effects in a combined texture figure detection and discrimination task. Performance for double-cue targets was better than predicted by independent processing of either cue and even better than predicted from linear cue integration. Application of a texture-processing model revealed that the oversummative cue combination effect is captured by calculating a low-level summary statistic (\(\Delta CE_m\)), which describes the differential contrast energy to target and reference textures, from multiple scales and orientations, and integrating this statistic across channels wi…

AdultMaleorientation bandwidthlocal energyComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONModels PsychologicalTexture (geology)Article050105 experimental psychologyContrast SensitivityYoung Adult03 medical and health sciences0302 clinical medicineHumans0501 psychology and cognitive sciencesDetection theorySensitivity (control systems)Orientation SpatialMathematicsspatial frequency bandwidthcue combinationOrientation (computer vision)Noise (signal processing)business.industry05 social sciencesPattern recognitionFilter (signal processing)Sensory SystemsOphthalmologyPattern Recognition VisualFemaleSpatial frequencyArtificial intelligencebusinesstexture segregation030217 neurology & neurosurgeryEnergy (signal processing)Journal of Vision
researchProduct

Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms

2021

Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical …

AdultMalepharmacological treatment of vertigomedicine.medical_specialtyCinnarizineHealth Toxicology and MutagenesisDiseasedimenhydrinateArticleCinnarizine Dimenhydrinate Dizziness Pharmacological treatment of vertigo Vertigo Adult Double-Blind Method Drug Combinations Female Histamine H1 Antagonists Humans Male Middle Aged Cinnarizine Dimenhydrinatevertigo03 medical and health sciences0302 clinical medicinePharmacotherapyDouble-Blind MethodVertigoInternal medicinemedicineotorhinolaryngologic diseasesHumans030212 general & internal medicinecinnarizine030223 otorhinolaryngologydizzinessBalance (ability)biologybusiness.industryPublic Health Environmental and Occupational HealthRMiddle Agedbiology.organism_classificationDimenhydrinateDrug CombinationsTolerabilityConcomitantHistamine H1 AntagonistsMedicineFemalebusinessmedicine.drug
researchProduct

Effect of continuous oestradiol-medroxyprogesterone administration on plasma lipids and lipoproteins

1991

Plasma lipids and lipoproteins were measured in 21 post-menopausal women after 4 and 8 months of continuous treatment with an orally administered combination of oestradiol and medroxyprogesterone acetate. The mean concentrations of cholesterol and low-density-lipoprotein (LDL) cholesterol were reduced by 12% (P less than 0.001) and 11% (P less than 0.01), respectively, after 4 months of treatment and by 9% (P less than 0.05) and 12% (P less than 0.05) after 8 months. The mean level of high-density-lipoprotein (HDL) cholesterol showed an initial fall of 5% (P less than 0.05) after 4 months and then increased by 13% (P less than 0.05) after 8 months of treatment. The plasma triglycerides leve…

AdultMedroxyprogesteronemedicine.medical_specialtymedicine.drug_classLipoproteinsMedroxyprogesteronemedicine.medical_treatmentGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundInternal medicinePlasma lipidsHumansMedicineMedroxyprogesterone acetateClinical significanceProspective StudiesEstradiolProgestogenbusiness.industryCholesterolEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedLipidsEndocrinologychemistryEstrogenDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Menopausebusinessmedicine.drugLipoproteinMaturitas
researchProduct

Metoclopramide and diphenhydramine in the treatment of hyperemesis gravidarum: effectiveness and predictors of rehospitalisation.

2007

Abstract Objectives Hyperemesis gravidarum (HG) is the second most common reason for hospitalisation during pregnancy. Since 2002, a new HG treatment protocol consisting of metoclopramide plus diphenhydramine was put in place at CHU Sainte-Justine, affiliated to University of Montreal, Quebec, Canada. The objectives of this study were to evaluate the effectiveness of this new HG protocol regarding length of hospitalisation for HG, rate of rehospitalisation, evolution of nausea and vomiting symptoms, and rate of adverse events. Study design A retrospective cohort study was conducted from 2002 to 2006 on the population of pregnant women diagnosed with HG, and treated at CHU Sainte-Justine wit…

AdultMetoclopramideAdolescentNauseamedicine.drug_classMetoclopramidePopulationPatient ReadmissionCohort StudiesHyperemesis gravidarumYoung AdultSex FactorsPregnancyHyperemesis GravidarumMorning sicknessmedicineAntiemeticHumanseducationRetrospective Studieseducation.field_of_studybusiness.industryDiphenhydraminePregnancy OutcomeObstetrics and GynecologyLength of Staymedicine.diseaseDiphenhydramineTreatment OutcomeReproductive MedicineAnesthesiaAntiemeticsDrug Therapy CombinationFemalemedicine.symptombusinessDroperidolmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Clinical and immunohistochemical evaluation of the vulvar Langerhans cell histiocytosis.

2008

:  We present the case of a woman with diabetes insipidus with subsequent genital and multiorgan Langerhans cell histiocytosis (LCH). A monolateral and slightly infiltrated erythematous plaque of the vulva was observed. Hematoxylin and eosin and immunophenotypic studies were performed. The primary antibodies used were monoclonal antibody to S100, CD1a, CD34, HLA-DR, PCNA, CD45Ro, CD40, and langerin. The histology of the infiltrates revealed a granulomatous reaction pattern, with extensive aggregates of histiocyte proliferation. The histiocytes, morphologically characterized by a pale staining of cytoplasm surrounding a grooved reniform nucleus, sometimes contained small distinct nucleoli. L…

AdultPathologymedicine.medical_specialtyCell typeLangerhans cellLangerinDermatologyVinblastineMethylprednisoloneImmunophenotypingVulvaLangerhans cell histiocytosisErythematous plaqueSettore MED/35 - Malattie Cutanee E VenereemedicineHumansHistiocyteCD40integumentary systembiologyHistiocytesGeneral Medicinemedicine.diseaseImmunohistochemistryHistiocytosis Langerhans-Cellmedicine.anatomical_structureTreatment Outcomevulvar Langerhans cell histiocytosisGiant cellErythemaLangerhans Cellsbiology.proteinDrug Therapy CombinationFemaleDiabetes InsipidusDermatologic therapy
researchProduct

Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis

2018

Autoimmune hepatitis (AIH) frequently affects women of childbearing age in whom the desire to have a family raises the question regarding the potential risks for the fetus and the mother. The information on AIH in pregnant patients is scarce.1 The aims of this study were (1) to identify the risk factors associated with flares in pregnant patients diagnosed with AIH, (2) to determine the course of AIH in patients with pregnancy-related flares, and (3) to describe the outcome of AIH diagnosed in the postpartum period.

AdultPediatricsmedicine.medical_specialtyAutoimmune hepatitisCohort Studies03 medical and health sciences0302 clinical medicinePregnancyimmune system diseasesAzathioprinemedicineHumansIn patientAspartate AminotransferasesGlucocorticoidsreproductive and urinary physiologyRetrospective StudiesPregnancyHepatologybusiness.industryPostpartum PeriodPregnancy OutcomeGastroenterologyAlanine TransaminaseHypertension Pregnancy-InducedSymptom Flare Upmedicine.diseasedigestive system diseasesAbortion SpontaneousPregnancy ComplicationsDiabetes GestationalHepatitis Autoimmune030220 oncology & carcinogenesisChildbearing agePrednisoneDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPresentation (obstetrics)businessImmunosuppressive AgentsPostpartum periodClinical Gastroenterology and Hepatology
researchProduct

Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma

2019

Despite the use of preferred controller therapies (including inhaled corticosteroids [ICS] with or without additional long-acting β2-agonists [LABAs]), a large proportion of patients with asthma have poor disease control, leaving them at risk of recurring symptoms and episodes of asthma exacerbations and worsening [1, 2]. Such problems can be triggered by many different environmental factors including pollutants, respiratory infections or allergens [3]. They may occur sporadically, but are often determined by seasons, mirroring seasonal patterns of allergen exposure and prevalence of respiratory viral infection [3, 4]. They can cause reduced quality of life, increase asthma burden [2, 3], a…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthma03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Administration InhalationmedicineHumans030212 general & internal medicineTiotropium BromideAsthmaWork productivitybusiness.industryConflict of interestmedicine.diseaseAsthmaBronchodilator AgentsAdd on therapy030228 respiratory systemFamily medicineAbsenteeismDrug Therapy CombinationSeasonsALLERGEN EXPOSUREbusinessEuropean Respiratory Journal
researchProduct

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss…

2003

Objective To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL). Methods We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the th…

Adultmedicine.medical_specialtyAbortion HabitualAdolescentmedicine.drug_classImmunologyLow molecular weight heparinGastroenterologyRoute of administrationRandom AllocationRheumatologyAntiphospholipid syndromePregnancyInternal medicinemedicineImmunology and AllergyHumansPharmacology (medical)PregnancyLupus anticoagulantAspirinAspirinbusiness.industryAnticoagulantPregnancy OutcomeAnticoagulantsImmunoglobulins IntravenousHeparinHeparin Low-Molecular-Weightmedicine.diseaseAntiphospholipid SyndromeSurgeryPregnancy ComplicationsTreatment OutcomeDrug Therapy CombinationFemalebusinessmedicine.drugArthritis and rheumatism
researchProduct

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1993

Abstract Background: The role of azathioprine (AZA) in the treatment of active Crohn's disease (CD) is still controversial. This study examined whether AZA combined with standard prednisolone therapy improved the therapeutic outcome compared with monotherapy with prednisolone. Methods: Forty-two patients with a Crohn's Disease Activity Index (CDAI) of > 150 were randomized into two groups. Both received 60 mg of prednisolone daily in a tapering regimen to a maintenance dose of 10 mg. In addition, group 1 received 2.5 mg AZA/kg body wt and group 2 received a placebo over the whole study period of 4 months. Results: At the end of the trial, 16 of 21 patients (76%) in group 1 were in remission…

Adultmedicine.medical_specialtyAdolescentPrednisolonemedicine.medical_treatmentAzathioprinePlaceboGastroenterologylaw.inventionCrohn DiseaseRandomized controlled triallawInternal medicineAzathioprinemedicineHumansChemotherapyHepatologybiologyMaintenance dosebusiness.industryC-reactive proteinGastroenterologyMiddle AgedSurgeryRegimenTreatment OutcomePrednisolonebiology.proteinDrug Therapy Combinationbusinessmedicine.drugGastroenterology
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct